key: cord-0686196-uqg79w3n
authors: Simon, David; Tascilar, Koray; Schmidt, Katja; Manger, Bernhard; Weckwerth, Leonie; Sokolova, Maria; Bucci, Laura; Fagni, Filippo; Manger, Karin; Schuch, Florian; Ronneberger, Monika; Hueber, Axel; Steffen, Ulrike; Mielenz, Dirk; Herrmann, Martin; Harrer, Thomas; Kleyer, Arnd; Krönke, Gerhard; Schett, Georg
title: Brief Report: Humoral and cellular immune responses to SARS‐CoV‐2 infection and vaccination in B cell depleted autoimmune patients
date: 2021-07-01
journal: Arthritis Rheumatol
DOI: 10.1002/art.41914
sha: 1bd110d068754ef2c36dcecb615d909aca8bc1c6
doc_id: 686196
cord_uid: uqg79w3n

OBJECTIVE: B cell depletion is an established therapeutic principle in a wide range of autoimmune disease. However, B cells are also critical for inducing protective immunity after infection and vaccination. We therefore assessed humoral and cellular immune responses after infection with or vaccination against severe acute respiratory syndrome coronavirus ‐2 (SARS‐CoV‐2) in B cell depleted patients and B cell competent healthy controls. METHODS: Antibody (ELISA) and T cell (IFNγ ELISPOT) responses against the SARS‐CoV‐2 spike S1 and nucleocapsid proteins were assessed in a limited number of infected (N=6) and vaccinated (N=8) B cell depleted autoimmune patients as well as infected (N=30) and vaccinated (N=30) healthy controls. RESULTS: As expected, B and T cell responses to the nucleocapsid were observed only after infection, while respective responses to spike S1 were found both after infection and vaccination. A SARS‐CoV‐2 antibody response was observed in all vaccinated controls (30/30, 100%) but in none (0/8) of the vaccinated B‐cell‐depleted patients. In contrast, after SARS‐CoV‐2 infection, both B‐cell‐depleted patients (spike S: 5/6, 83%; nucleocapsid 3/6, 50%) and healthy controls (spike S: 28/30, 94%; nucleocapsid 28/30, 93%) developed antibodies. T cell responses against the spike S1 and nucleocapsid proteins were found in both infected and vaccinated B cell depleted subjects and in the controls. CONCLUSION: These data show that B cell depletion completely blocks humoral but not T cell SARS‐CoV‐2 vaccination response. Furthermore, limited humoral immune responses are found in B cell depleted patients after SARS‐CoV‐2 infection.

Depletion of B cells is an effective therapeutic strategy to treat severe autoimmune disease (1) .

Diseases with robust activation of B cells and plasma cells, such as rheumatoid arthritis (2), multiple sclerosis (3), granulomatosis with polyangiitis (4), dermatomyositis (5), IgG4 syndrome (6) , pemphigus (7) and immune thrombocytopenic purpura (8) are sensitive to B cell targeting. Rituximab, a monoclonal antibody binding the B cell specific surface molecule CD20, effectively depletes circulating B cells over a period of several months and shows widespread therapeutic efficacy in patients with autoimmune disease (9) . B cell depletion, however, may also seriously impair the development of protective immunity after infection and vaccination. Of note, rituximab treatment has been associated with more severe courses of COVID-19 (10) and impaired immune response to established vaccines (11, 12) . To date, reliable data on the impact of B-cell depletion on the dynamics of protective antibody responses upon infection and vaccination remain sparse (13) , while protective antibody responses have been clearly documented in naïve (14) and previously infected (15) immune competent subjects. The current SARS-CoV-2 pandemic thus provides an unique opportunity to profile the immune response of a naïve population to a defined infectious agent. In addition, it permits to study quality and quantity of a newly evolving adaptive immune response to infection and to vaccination in both healthy individuals and in B-cell depleted patients, respectively.

This article is protected by copyright. All rights reserved Methods Ethical Approval Ethical approval (#157_20 B) to conduct this analysis was granted by the institutional review board of the University Clinic of Erlangen as the responsible ethics committee. Written informed consent was obtained from the study participants.

Sera of rituximab-treated patients and healthy controls were collected within the COVID-19 study program of the Deutsche Zentrum fuer Immuntherapie (DZI) (16) . This study program has been initiated in February 2020 and monitors anti-SARS-CoV-2 antibody responses in healthy controls, COVID-19 patients and autoimmune patients (16) . Healthy controls did not have an immune-mediated inflammatory disease nor did they receive any treatment with immune-modulatory agents. Vaccinated patients and vaccinated healthy controls did not have any history of COVID-19 or positive COVID-19 PCR before the analysis.

Rituximab-treated patients and healthy controls were vaccinated with BNT162b2 mRNA SARS-CoV-2 vaccine at official public vaccination centers based on occupational exposure risk, comorbidities and age-related risk in accordance with the recommendations of the Robert Koch Institute (RKI). Sera were collected at least 10 days after the second vaccination and at least 30 days after onset of infection in the infected participants. In all participants we collected demographic data (age, sex) as well as disease-specific data (type of autoimmune disease, type of treatment). Mean elapsed time between antibody testing and infection (3.8 months; range 1-8; SD 2.9) or vaccination (3.6 months; range 1-8; SD 3.0), respectively, was very similar in the rituximab-treated patients. Mean number of rituximab infusions was 5.4±4.3, administered at a dose of 1000 mg every 6 months.

This article is protected by copyright. All rights reserved Anti-SARS-CoV-2 antibodies IgG antibodies against the S1 domain of the spike protein and nucleocapsid protein of SARS-CoV-2 were tested by two CE commercial enzyme-linked immunosorbent assay (Euroimmun, Lübeck, Germany; Epitope Diagnostics, USA) according to the manufacturers protocols. Optical density was determined at 450 nm with reference wavelength at 630 nm. A cutoff of <0.8 and <0.2 was considered as negative for IgG antibodies against spike S1 protein and nucleocapsid, respectively. An in-house neutralization assay for assessment of inhibition of binding to ACE2 by antibodies was used. Assays According to the manufacturer's guidelines, a response was considered positive when the number of Accepted Article spots in the respective panel was ≥ 8 SFUs above the negative control. Samples with negative controls > 10 SFUs were considered invalid.

Subject characteristics were summarized using means and standard deviations for continuous data and counts and percentages for categorical data. We used Wilcoxon's rank-sum test for pairwise betweengroup comparisons of optical density from the anti-spike S1 IgG and anti-nucleocapsid IgG assays. P values were adjusted for a family of 6 possible pairwise comparisons per assay using the Bonferroni-Holm method and considered significant when <0.05.

To address the question, whether autoimmune patients depleted from peripheral B cells are able to develop specific humoral immunity to SARS-CoV-2 vaccination, we screened data from an ongoing longitudinal SARS-CoV-2 antibody study in Germany, which measures IgG responses against the SARS-CoV-2 spike S1 protein (Euroimmun, Lübeck, Germany) and the nucleocapside (Epitope Diagnostics, USA) in patients with autoimmune inflammatory diseases and healthy controls (16) . We identified 8 rituximab-treated patients that received the Peripheral B cells were undetectable or lower than 15 cells/microliter in all infected and vaccinated patients. Also, Peripheral CD4 and CD8 T cell counts as well as serum levels of immunoglobulins IgG, IgA and IgM did not differ between infected and vaccinated rituximab-treated patients ( Figure 1B) . We were also able to assess SARS-CoV-2 specific Tcell responses using an IFN-gamma ELISpot assay in a limited subset of the patients from each group ( Figure 1C ). T cell responses against both the spike S1 protein and the nucleocapsid were found in healthy controls and B cell depleted patients after SARS-CoV-2 infection. Furthermore, also the majority of vaccinated patients, including the ones depleted for B cells, developed a T cell response against the spike S1 protein, while, as expected no T cell responses against the nucleocapsid were found in the vaccinated patients. In addition, the data also suggest that potentially protective T cell-mediated immunity may develop after the vaccination in the absence of B cells.

A limitation of this study is the limited number of B cell depleted patients exposed to SARS-CoV-2 infection and vaccination. Though results were highly consistent even in this small sample, further studies will be required. Furthermore, only BNT162b2 mRNA SARS-CoV-2 vaccine was assessed in this data set requiring the collection of additional data from other, i.e.

vector-based vaccines. Despite these limitations, the data very consistently showed that T cell responses against SARS-CoV-2 can develop in both vaccinated and infected B cell depleted patients. The data also indicate that SARS-CoV-2 infection, but not vaccination can in

This article is protected by copyright. All rights reserved Anti-Spike S1 IgG >OD 0. 

Modulating immunity to treat autoimmune disease

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

Rituximab versus cyclophosphamide for ANCA-associated vasculitis

Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial

Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease

A single cycle of rituximab for the treatment of severe pemphigus

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

Covid-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

The effect of rituximab on vaccine responses in patients with immune thrombocytopenia Blood

Accepted Article This article is protected by copyright. All rights reserved

SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Antibody responses to theBNT162b2mRNA vaccine in individuals previously infected with SARS-CoV-2

Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis

Antibodies against the spike S1 protein (left; Euroimmun ELISA) and the nucleocapsid (middle

Epitope Diagnostics ELISA) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Tests were done in 30 healthy controls after SARS-CoV-2 infection (CTRL-COVID-19), 30 healthy controls after SARS-CoV-2 mRNA vaccination

RTX-COVID19) and 8 rituximab-treated B-cell depleted patients with autoimmune disease after SARS-CoV-2 mRNA vaccination (RTX-VACC) Y-axis shows optical density (OD) at 450 nanometer. Each dot represents one patient. Comparisons were done by Wilcoxon´s signed rank-sum test. (right) correlation of neutralizing antibody activity (in % inhibition of binding of spike S1 protein expressing cells to ACE2

spike S1 protein IgG in infected controls and rituximab-treated patients (B) (top) serum Accepted Article This article is protected by copyright. All rights reserved immunoglobulin G (IgG), immunoglobulin A (IgA) and immunoglobulin M (IgM) levels and (bottom) peripheral CD19 B cell, CD4 T cell and CD8 T cell numbers in rituximab-treated SARS-CoV-2 infected (RTX-COVID19) and vaccinated

Y-axis shows spot forming units (SFU). T cell responses were analyzed in healthy controls after SARS-CoV-2 infection (CTRL-COVID-19) and after SARS-CoV-2 mRNA vaccination (CTRL-VACC) as well as in rituximab-treated B-cell depleted patients after SARS-CoV-2 infection

Accepted Article